HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Mass. "Right to Know" Act

This article was originally published in The Rose Sheet

Executive Summary

Mass. "Right to Know" Act: Passes out of Natural Resources Committee Oct. 7 and returns to the Senate for a second reading. The "Proposition 65" clone (S 488) would require warning labels on cosmetics and consumer products containing ingredients the state deems to cause cancer, reproductive toxicity, developmental toxicity or neurotoxicity ("The Rose Sheet" May 12, p. 8). The committee amended the bill, with "no significant risk" explained as a "reasonable likelihood that no harm will result from exposure," rather than the measure's previous "one-cancer-in-a-million" standard. An "adequate margin of safety" definition is also added, with the margin set 1,000 times above the no-effect level, adjustable in cases where a chemical is an essential nutrient or adequate dose-response data exist to suggest a lower margin would be appropriate. S 488 is not likely to conflict with federal national uniformity legislation because the measure would exempt exposures "for which federal law governs warnings in a manner the pre-empts state authority," the bill states. CTFA continues to oppose the bill...

Mass. "Right to Know" Act: Passes out of Natural Resources Committee Oct. 7 and returns to the Senate for a second reading. The "Proposition 65" clone (S 488) would require warning labels on cosmetics and consumer products containing ingredients the state deems to cause cancer, reproductive toxicity, developmental toxicity or neurotoxicity ("The Rose Sheet" May 12, p. 8). The committee amended the bill, with "no significant risk" explained as a "reasonable likelihood that no harm will result from exposure," rather than the measure's previous "one-cancer-in-a-million" standard. An "adequate margin of safety" definition is also added, with the margin set 1,000 times above the no-effect level, adjustable in cases where a chemical is an essential nutrient or adequate dose-response data exist to suggest a lower margin would be appropriate. S 488 is not likely to conflict with federal national uniformity legislation because the measure would exempt exposures "for which federal law governs warnings in a manner the pre-empts state authority," the bill states. CTFA continues to oppose the bill....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel